Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: pioglitazone HCl 45 mg Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation

NCT00470262
View directory record Official record
Conditions
Metabolic Syndrome X, Prediabetic State
Interventions
Fenofibrate 145mg PO QD, Pioglitazone 45 mg PO QD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 4, 2026, 5:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

NCT00179400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone, Placebo, Pancreatic Clamp Study
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

NCT00300365
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pioglitazone, Placebo, Niacin ER, Aspirin
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional

"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM

NCT00402012
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg

NCT00649012
View directory record Official record
Conditions
Healthy
Interventions
Pioglitazone HCl Tablets 45 mg, Actos® Tablets 45 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

NCT00121667
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin + Metformin, Placebo + Metformin, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
95
States / cities
Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 3 Interventional

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
110
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 4, 2026, 5:49 AM EDT
Active, not recruiting Phase 2 Interventional

The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia

NCT05919147
View directory record Official record
Conditions
Lung Cancer
Interventions
Pioglitazone 45 mg, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanisms Underlying Metabolic Syndrome in Obesity

NCT00579813
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, Prediabetes
Interventions
Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT02222441
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

NCT00554853
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
pioglitazone, Sublingual nitroglycerine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Actos Now for Prevention of Diabetes (ACT NOW)

NCT00220961
View directory record Official record
Conditions
Impaired Glucose Tolerance, Type 2 Diabetes
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

NCT04370093
View directory record Official record
Conditions
Nephrolithiasis, Uric Acid
Interventions
Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Study of Rivoglitazone in Type 2 Diabetes Mellitus

NCT00484198
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pioglitazone, Placebo, Rivoglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
70
States / cities
Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics

NCT00634036
View directory record Official record
Conditions
Asthma
Interventions
pioglitazone, placebo
Drug
Lead sponsor
Fernando Holguin
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

NCT00331487
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Rosiglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
67
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

NCT01432405
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

NCT00926016
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pioglitazone (Actos)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

NCT01103414
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mitoglitazone, Pioglitazone, Placebo
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 4, 2026, 5:49 AM EDT